In This Article:
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.
Corcept beat analysts’ revenue expectations by 6.2% last quarter, reporting revenues of $182.5 million, up 47.7% year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ EPS estimates.
Is Corcept a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Corcept’s revenue to grow 46.8% year on year to $198.7 million, improving from the 31.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Corcept has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Corcept’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Pfizer delivered year-on-year revenue growth of 21.9%, beating analysts’ expectations by 3%, and Eli Lilly reported revenues up 44.7%, in line with consensus estimates. Pfizer’s stock price was unchanged after the results, while Eli Lilly was up 4.2%.
Read our full analysis of Pfizer’s results here and Eli Lilly’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the branded pharmaceuticals stocks have shown solid performance, the group has generally underperformed, with share prices down 5.3% on average over the last month. Corcept is up 3% during the same time and is heading into earnings with an average analyst price target of $97 (compared to the current share price of $59.77).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.